Optimer files IPO in bid to raise $86.3M

Optimer Pharmaceuticals has filed to go public in an IPO designed to raise $86.3 million. Piper Jaffray and Jeffries & Co. are the lead underwriters. Earlier this year Optimer announced that its therapy for infectious diarrhea was markedly successful in a small Phase II trial. OPT-80 cured 41 of the 45 patients in the study. Antibiotics have become popular with investors as a new generation of antibiotic-resistant infections has gained traction in the population. OPT-80 is currently in a Phase IIb-III trial and OPT-99 is in Phase III for traveler's diarrhea. Optimer is was a 2006 Fierce 15 winner.

- see the release on Optimer's IPO

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.